Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): A novel candidate for systemic and local therapy of postinterventional restenosis

Coronary Artery Disease

Volumn 21, Issue 5, 2010, Pages 286-291

  Voisard, Rainer ^a   Krebs, Ricarda ^a   Baur, Regine ^a   Hombach, Vinzenz ^a  

^a UNIVERSITY OF ULM   (Germany)

Author keywords

drug eluting stents; migration; proliferation; restenosis; valproic acid

Indexed keywords

VALPROIC ACID;

ARTICLE; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CORONARY ARTERY; CORONARY BLOOD VESSEL; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; RESTENOSIS; SMOOTH MUSCLE FIBER; CELL CULTURE; CELL MOTION; CELL SURVIVAL; CORONARY RESTENOSIS; DRUG EFFECTS; ENDOTHELIUM CELL; PATHOLOGY; TIME; TOXICITY; VASCULAR SMOOTH MUSCLE;

CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CORONARY RESTENOSIS; CORONARY VESSELS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; TIME FACTORS; VALPROIC ACID;

EID: 77954658208     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3283349cd7     Document Type: Article

References (25)

1. Blaheta RA, Nau H, Michaelis M, Cinatl J Jr. Valproate and valproateanalogues: potent tools to fight against cancer. Curr Med Chem 2002; 9:1417-1433.
2. Munster P, Marchion D, Bicaku E, Schmitt M, Lee JH, DeConti R, et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitior epirubicin in advanced soild tumors: a clinical and translational study. J Clin Oncol 2007; 25:1879-1985.
3. Duenas-Gonzalez A, Candelaria M, Perez-Plascencia C, Perez-Cardenas E, de la Cruz-Hernandez E, Herrera LA. Valproic acid as epigenetic cancer drug, preclinical, clinical and transcriptional effects on solid tumor. Cancer Treat Rev 2008; 34:206-222.
4. Dartsch PC, Voisard R, Bauriedel G, Höfling B, Betz E. Growth characteristics and cytoskeletal organization of cultured smooth muscle cells from human primary stenosing and restenosing lesions. Arteriosclerosis 1990; 10:62-75.
5. Bauriedel G, Windstetter U, DeMaio SJ Jr, Kandolf R, Höfling B. Migratory activity of human smooth muscle cells culivated from coronary and peripheral primary and restenotic lesions removed by percutaneous atherectomy. Circulation 1992; 85:554-564.
6. Voisard R, Baur R, Herter T, Herter T, Hombach V. Two decades of failing systemic restenosis trials: clinical relevance of positive in vitro data. Perfusion 2004; 17:186-197.
7. Voisard R, Dartsch PC, Seitzer U, Hannekum A, Roth D, Kochs M, Hombach V. The in-vitro effect of antineoplastic agents on proliferative activity and cytoskeletal components of plaque-derived smooth-muscle cells from human coronary arteries. Coron Artery Dis 1993; 4:935-942.
8. Chatterjee S, Pandey A. Drug eluting stents: friends or foe? A review of cellular mechanisms behind the effects of Paclitaxel and sirolimus elutings stents. Curr Drug Metab 2008; 9:554-566.
9. Voisard R, Zellmann S, Müller F, Fahlisch F, von Müller L, Baur R, et al. Sirolimus inhibits key events of restenosis in vitro/ex vivo: evaluation of the clinical relevance of the data by SI/MPL- and SI/DES-ratios. BMC Cardiovasc Disord 2007; 7:15.
10. Jaffe EA, Nachman RL, Becker CG, Minick R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 71:2845-2856.
11. Franssen EJ, van Essen GG, Portman AT, de Jong J, Go G, Stegeman CA, Uges DR. Valproic acid toxicokinetics: serial hemodialysis and hemoperfusion. Ther drug Monit 1999; 21:289-292.
12. Voisard R, Koschnick S, Baur R, Vogel U, Mattfeldt T, Hemmer W, et al. High dose diltiazem prevents migration and proliferation of vascular smooth muscle cells in various in-vitro models of human coronary restenosis. Coron Artery Dis 1997; 8:189-201.
13. Voisard R, Seitzer U, Baur R, Dartsch PC, Osterhues H, Höher M, Hombach V. Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. Int J Cardiol 1994; 43:257-267.
14. Knüpfer MM, Pulzer F, Schindler I, Driever PH, Knüpfer H, Keller E. Different effects of valproic acid on proliferation and migration of malignant glioma cells in vitro. Antican Res 2001; 21:347-352.
15. Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, Blaheta RA. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in in vivo. J Cell Mol Med 2008; 12:1-10.
16. Jones J, Bentas W, Blaheta RA, Makarevic J, Hudak L, Wedel S, et al. Modulation of adhesion and growth of colon and pancreatic cancer cells by histone deacetylase inhibitor valproic acid. Int J Mol Med 2008; 22:293-299.
17. Kleinman HK, Jacob K. Invasion assays. Curr Protoc Cell Biol 2001; 12:12.2.
18. Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opinion Oncol 2001; 13:477-483.
19. Vigushin DM, Coombes RC. Histone deactelyse inhibitors in cancer treatment. Anticancer Drugs 2002; 12:1-13.
20. Rosato RR, Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol Therap 2003; 2:30-37.
21. Marchion DC, Bicaku E, Daud AI, Sullivan DM, Munster PN. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005; 65:3815-3822.
22. Catalano MG, Fortunati N, Pugliese M, Poli R, Bosco O, Mastrocola R, et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J Endocrinol 2006; 191:465-472.
23. Catalano MG, Poli R, Pugliese M, Fortunati N, Boccuzzi G. Valproic acid enhances tubulin acetylation and apoptotic activity of paclitaxel on anaplastic thyroid cancer cell lines. Endocr Relat Cancer 2007; 14:839-845.
24. Das CM, Aguilera D, Vasquez H, Prasad P, Zhang M, Wolff JE, Gopalakrishnan V. Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines. J Neurooncol 2007; 85:159-170.
25. Voisard R, Gecgüner L, Baur R, Herter T, Hombach V. Antiproliferative profile of sirolimus and mycophenolate mofetil: impact of the S/MPL-ratio. Int J Cardiol 2005; 102:435-442.